Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.
复制标题

DOI:
10.1007/s11060-017-2458-0
复制
发表时间:
2017-09
影响因子:
3.9
通讯作者:
Ahmed MM
Ahmed MM
中科院分区:
医学2区
文献类型:
--
作者:
Kunos CA;Galanis E;Buchsbaum J;Shi Q;Strauss LC;Coleman CN;Ahmed MM

文献摘要

参考文献

相似文献

胶质母细胞瘤是一种侵袭性疾病,其特征是对一线放化疗干预的初始应答率适中,对二线干预的应答率低。这篇文章讨论了在NCI-NCTN环境下为原发和复发的胶质母细胞瘤的放射和研究药物组合临床试验开发的新的战略平台,同时分析了药物开发过程中的挑战。
Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.
DOI: 10.1093/neuonc/not161
发表时间: 2014-01-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Hutterer, Markus;Nowosielski, Martha;Stockhammer, Guenther
通讯作者: Stockhammer, Guenther
DOI: 10.3171/jns.1979.51.4.0526
发表时间: 1979-01-01
影响因子: 4.1
作者:
LEVIN, VA;WILSON, CB;IRWIN, L
通讯作者: IRWIN, L
DOI: 10.1056/nejmoa043331
发表时间: 2005-03-10
影响因子: 158.5
作者:
Hegi, ME;Diserens, A;Stupp, R
通讯作者: Stupp, R
DOI: 10.1158/1078-0432.ccr-13-0708
发表时间: 2013-09-01
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Galanis E;Anderson SK;Lafky JM;Uhm JH;Giannini C;Kumar SK;Kimlinger TK;Northfelt DW;Flynn PJ;Jaeckle KA;Kaufmann TJ;Buckner JC
通讯作者: Buckner JC
DOI: 10.1093/neuonc/nou328
发表时间: 2015-09-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Ma, Daniel J.;Galanis, Evanthia;Sarkaria, Jann N.
通讯作者: Sarkaria, Jann N.